# **Oncology Pulse**


New Oncology Agents – A Look Back and the Year Ahead

March 2025



Strategic Experts in the Business of Life Sciences

Targeted therapy has been the driver of new oncology approvals in recent history, but a more diverse mix of MOAs have been approved in the past few years



New Oncology Agents - 2021 to Present

Targeted therapies account for <50% of new approvals in past 5 years, down from >65% in the prior 5 years Half of drugs approved in 2024 had novel targets, like DLL3 and claudin18.2

The first cell therapies and T-cell engager for solid tumors approved in 2024

Wave of ADC dealmaking not yet impacting practice – Datroway only new ADC in 3 years, with established TROP2 target



\* FGFR, FLT3, IDH1, IDH2, MET, NTRK, PDGFR, PI3K, RET, KRAS G12C, ESR1, MAGEA-4, KMT2A Source: FDA; Bluestar analysis

## 9 of 18 drugs approved in 2024 have novel MOAs, including the first cell therapies and T-cell engager for solid tumors

#### 2024 New Oncology Agents

	Targeted	Cell/Gene Therapy	IO	Bispecific	ADC	Endocrine	Radiopharm/Other
Approved	Ojemda (RAF) Rytelo (telomerase) Voranigo (IDH1/2) Niktimvo (CSF1R) Lazcluze (EGFR) Itovebi (PI3K) Revuforj (menin) Vyloy (claudin 18.2) Ensacove (ALK)	<b>Amtagvi (TILs)</b> <b>Teceira (MAGEA4)</b> Aucatzyl (CD19)	<b>Anktiva (IL-15)</b> Tevimbra (PD-1) Unloxcyt (PD-L1)	<b>Imdelltra (DLL3xCD3)</b> Ziihera (HER2xHER2) <b>Bizengri (HER2xHER3)</b>			
Rejected/ Deferred			Camrelizumab (PD-1)	Odronextamab (CD20xCD3) Linvoseltamab (BCMAxCD3)	Patritumab-DXd (HER3)		lopofosine Iomab-B (CD45)

Select Novel MOAs

- Imdelltra (tarlatamab DLL3xCD3; Amgen): T-cell engager for 2L+ SCLC brings back to life ~5 years after failure of StemCentrx's Rova-T ADC
- Zolbetuximab (claudin18.2; Astellas): approval in gastric cancer was held up by a CMC issue; carves out a new segment in this high unmet need tumor type; potential to expand into other GI tumors and many claudin 18.2 ADCs hot on its heels
- Amtagvi and Tecelra: First solid tumor cell therapies (TILs and TCR, respectively) will provide insight into market dynamics for autologous therapies



Bold = novel target 3

Fewer new MOAs are anticipated in 2025, while the oral SERD class in HR+/HER2- breast cancer is poised for significant competition, with 4 pivotal readouts/approvals on the horizon

	Targeted	Cell/Gene Therapy	Ю	Bispecific	ADC	Endocrine	Radiopharm/Other
Approved					Datroway (TROP2)		
Filed	Avutometinib (RAS) + Defactinib (FAK) Dordaviprone (ClpP/DRD2) Sunvozertinib (EGFR ex20) Taletrectinib (ROS1) Zongertinib (HER2)		Penpulimab (PD-1) RP-1 (oncolytic virus)	Linvoseltamab (BCMAxCD3) Odronextamab (CD20xCD3)	Blenrep (BCMA) Telisotuzumab vedotin (MET)	Imlunestrant (oSERD)	Mitomycin gel (chemo)
Filing Expected	Ziftomenib (menin) <b>Rusfertide (hepcidin)</b>		Sasanlimab (PD-1)			Camizestrant (oSERD) Vepdegestrant (oSERD)	
Pivotal Readout Expected in 2025	Ceralasterib (ATR) Zongertinib (HER2) Zanzalintinib (multi-TKI) Bemarituzumab (FGFR) Iberdomide (CELMoD)		Fianlimab (LAG-3)		Zilovertamab vedotin (ROR1)	Giredestrant (oSERD)	

#### 2025 New Oncology Agents

Fewer new MOAs poised for approval compared to last year

Select Novel MOAs

- Ceralsertib (ATRi, AZ): Looking to replicate the success of Ph2 Hudson trial in PD-1 pretreated NSCLC
- Bemarituzumab (FGFR, Amgen): Could bring a new biomarker to the gastric cancer landscape, though initial Ph3 does not include now SoC PD-1
- Two new potential ADC targets: MET (teliso-v; AbbVie) for NSCLC and ROR1 (zilovertamab vedotin; Merck) for DLBCL



### Key Trends and Questions for 2025

Key Trends...

Early-stage setting takes center stage with IO and targeted therapy approvals

Cracking KRAS: next-gen G12C, first G12D and pan-(K)RAS emerging

Beyond PD-(L)1: SC formulations as lifecycle plays; many players chasing VEGF bispecifics

China licensing deals continue – picking up potentially "super me-too" assets in hot classes

TROP2 disappointments and TOP1 sequencing data take ADC enthusiasm down a notch



... Emerging Questions

How will ODAC 'contribution of parts' recommendation impact trial designs? Are surrogates like pCR, ctDNA ready for prime time?

Pros and cons of pan vs. specific inhibitors? How will order of entry impact opportunity and sequencing by tumor type?

Can VEGF bispecific/bifunctional approach deliver improved outcomes as PD-(L)1 LOEs near?

Are innovative molecules on the way? How long will the China licensing wave last given domestic funding environment?

Have we reached saturation for TOP1 payloads in clinical development? What novel payloads could emerge?

5

# #ASC025





ERIN OLSEN Managing Director MICHELLE WHANG Principal

We'll be at ASCO!



521 Fifth Avenue, 25<sup>th</sup> floor New York, NY 10175 Office: 212-257-6030 https://www.bluestarbioadvisors.com



### Disclaimer

This presentation has been prepared by Bluestar BioAdvisors LLC ("Bluestar") for the exclusive use of the party to whom Bluestar delivers this presentation (the "Company"). Bluestar makes no, and disclaims all, representations and warranties, express or implied, in relation to these materials and the information contained therein. Bluestar will not be liable for any direct, indirect, special, incidental, exemplary or consequential losses or damages of any kind, including without limitation those damages suffered by any person as a result of relying on any statement or information contained in these materials. To the extent the presentation includes estimates about market and product potential, as well as forecasts of future business or financial performance (including estimates of potential cost savings and synergies), such estimates and forecasts are made as of the effective date of the presentation, are not guarantees and must be independently considered and verified by Company. Actual results will vary from the projections and such variations may be material. Distribution of this presentation to any person other than the Company and those persons retained to advise the Company, who agree to maintain the confidentiality of this material and be bound by the limitations outlined herein, is unauthorized. This presentation has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instrument or as legal, tax, accounting or investment advice or recommendation. The Company should consult its own counsel, tax and financial advisors as to matters described herein.

